GSKGlaxoSmithKlineFinished
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
Lung Cancer, Non-Small Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 666 (final count)
- Started
- Oct 26, 2020
- Main results expected
- Feb 26, 2025
- Fully finished
- Mar 23, 2026
- Results posted
- May 1, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population
Measured over: Up to 52 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04475939 · record last updated 2026-06-18 · checked 2026-11-09 15:42 UTC